Seelos Therapeutics (SEELQ) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 08, 2013
Document Information	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'APRI	'
Entity Registrant Name	'APRICUS BIOSCIENCES, INC.	'
Entity Central Index Key	'0001017491	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	37,533,428

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$20,619	$15,130	[1]
Accounts receivable	35	653	[1]
Restricted cash	332	52	[1]
Inventories	338	0	[1]
Prepaid expenses and other current assets	338	582	[1]
Property held for sale	0	3,654	[1]
Current assets of discontinued operations	0	825	[1]
Total current assets	21,662	20,896	[1]
Property and equipment, net	549	601	[1]
Other long term assets	90	100	[1]
Restricted cash long term	0	343	[1]
Noncurrent assets of discontinued operations	0	1,940	[1]
Total assets	22,301	23,880	[1]
Current liabilities	'	'
Convertible notes payable, net	1,441	0	[1]
Trade accounts payable	615	2,277	[1]
Accrued expenses	2,180	1,841	[1]
Accrued compensation	780	2,521	[1]
Deferred revenue	45	536	[1]
Derivative liabilities	292	0	[1]
Deconsolidation of French Subsidiaries	2,846	0	[1]
Other current liabilities	201	57	[1]
Current liabilities of discontinued operations	0	3,536	[1]
Total current liabilities	8,400	10,768	[1]
Long term liabilities	'	'
Convertible notes payable, net	1,102	3,413	[1]
Derivative liability	194	906	[1]
Deferred compensation	531	1,529	[1]
Other long term liabilities	127	196	[1]
Noncurrent liabilities of discontinued operations	0	447	[1]
Total liabilities	10,354	17,259	[1]
Commitments and contingencies	'	'	[1]
Stockholders’ equity:	'	'
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2013 and December 31, 2012	0	0	[1]
Common stock, $.001 par value, 75,000,000 shares authorized, 37,533,428 and 29,937,669 issued and outstanding at September 30, 2013 and December 31, 2012, respectively	38	30	[1]
Additional paid-in-capital	278,630	257,078	[1]
Accumulated other comprehensive income	0	641	[1]
Accumulated deficit	-266,721	-251,128	[1]
Total stockholders’ equity	11,947	6,621	[1]
Total liabilities and stockholders’ equity	$22,301	$23,880	[1]
[1]	The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, par value (USD per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (USD per share)	$0.00	$0.00
Common stock, shares authorized	75,000,000	75,000,000
Common stock, issued	37,533,428	29,937,669
Common stock, outstanding	37,533,428	29,937,669

Consolidated_Statements_of_Ope

Consolidated Statements of Operations And Other Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
License fee revenue	$0	$3,626	$669	$4,299
Contract service revenue	28	1,269	1,480	1,269
Total revenue	28	4,895	2,149	5,568
Cost of service revenue	15	1,591	2,568	1,591
Gross profit (loss)	13	3,304	-419	3,977
Costs and expenses	'	'	'	'
Research and development	919	1,999	3,867	4,209
General and administrative	2,866	3,755	10,446	10,309
Gain on contract settlement	-534	0	-534	0
Recovery on sale of subsidiary	-75	-125	-180	-125
Deconsolidation of French Subsidiaries	0	0	-641	0
Total costs and expenses	3,176	5,629	12,958	14,393
Loss from continuing operations before other (expense) income	-3,163	-2,325	-13,377	-10,416
Other (expense) income	'	'	'	'
Interest expense, net	-174	-73	-618	-215
Rental income	0	115	91	340
Other income (expense), net	138	0	-331	-12
Total other (expense) income	-36	42	-858	113
Loss from continuing operations before benefit from income taxes	-3,199	-2,283	-14,235	-10,303
Benefit from income taxes	0	362	0	362
Loss from continuing operations	-3,199	-1,921	-14,235	-9,941
Income (loss) from discontinued operations	214	-573	-1,358	-2,193
Net loss	-2,985	-2,494	-15,593	-12,134
Basic and diluted loss per common share	'	'	'	'
Basic and diluted loss per common share Loss from continuing operations (USD per share)	($0.09)	($0.07)	($0.43)	($0.38)
Income (loss) from discontinued operations (USD per share)	$0.01	($0.02)	($0.04)	($0.08)
Net loss (USD per share)	($0.08)	($0.09)	($0.47)	($0.46)
Weighted average common shares outstanding used for basic and diluted loss per share (shares)	37,003,853	29,258,434	33,360,710	26,652,258
Other comprehensive income	'	'	'	'
Foreign currency translation adjustments	0	37	0	37
Comprehensive loss	($2,985)	($2,457)	($15,593)	($12,097)

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Stockholders' Equity (USD $)	Total		Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
In Thousands, except Share data, unless otherwise specified
Beginning Balance at Dec. 31, 2012	$6,621	[1]	$30	$257,078	$641	($251,128)
Beginning Balance (shares) at Dec. 31, 2012	'		29,937,669	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'		'	'	'	'
Issuance of compensatory restricted stock to employees, consultants and Board of Director members (shares)	'		87,669	'	'	'
Stock-based compensation expense	1,622		'	1,622	'	'
Issuance of common stock, net of offering costs (shares)	'		312,450	'	'	'
Issuance of common stock, net of offering costs	792		'	792	'	'
Issuance of common stock and warrants, net of offering costs (shares)	'		6,000,000	'	'	'
Issuance of common stock and warrants, net of offering costs	15,820		6	15,814	'	'
Issuance of common stock upon exercise of convertible notes (shares)	486,923		486,923	'	'	'
Issuance of common stock upon exercise of convertible notes	1,737		1	1,736	'	'
Issuance of holdback shares in the form of common stock to TopoTarget (shares)	'		688,717	'	'	'
Issuance of holdback shares in the form of common stock to TopoTarget	1,543		1	1,542	'	'
Issuance of common stock upon exercise of warrants (shares)	'		20,000	'	'	'
Issuance of common stock upon exercise of warrants	46		'	46	'	'
Elimination of cumulative translation adjustment upon deconsolidation of French Subsidiaries	-641		'	'	-641	'
Net loss	-15,593		'	'	'	'
Ending Balance at Sep. 30, 2013	$11,947		$38	$278,630	$0	($266,721)
Ending Balance (shares) at Sep. 30, 2013	'		37,533,428	'	'	'
[1]	The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012
Cash flows from operating activities of continuing operations:	'		'
Net loss	($15,593)		($12,134)
Loss from discontinued operations	-1,358		-2,193
Net loss from continuing operations	-14,235		-9,941
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities of continuing operations:	'		'
Deconsolidation of French Subsidiaries	-641		0
Gain on contract settlement	-534		0
Depreciation and amortization	57		510
Accretion of debt discount	192		0
Stock-based compensation expense	-1,622		-1,722
Changes in derivative liabilities	243		0
Accretion of interest on contingent consideration	242		0
Other	17		-2
Changes in operating assets and liabilities of continuing operations, net of assets and liabilities acquired and divested in business acquisitions and divestitures:	'		'
Accounts receivable	276		-2,491
Inventories	-338		-109
Prepaid expenses and other current assets	-63		-926
Deferred rental income and other assets	1		-436
Accounts payable	-1,502		279
Accrued expenses	-39		562
Accrued compensation	-917		0
Deferred revenue	-248		225
Deferred compensation	-165		68
Other liabilities	-21		171
Net cash used in operating activities from continuing operations	-16,053		-10,368
Cash flows from investing activities of continuing operations:	'		'
Purchase of fixed assets	-119		-23
Proceeds from the sale of property and equipment	3,657		2
Investment in intangible assets	0		836
Cash acquired from Finesco	0		1,855
Elimination of bank deficit in deconsolidated French Subsidiaries	270		0
Deposit of restricted cash	-280		0
Net cash provided by investing activities from continuing operations	3,528		2,670
Cash flows from financing activities of continuing operations:	'		'
Proceeds from exercise of warrants	46		40
Proceeds from the exercise of stock options	0		10
Repayment of capital lease obligations	0		-3
Issuance of common stock, net of offering costs	16,612		19,489
Net cash provided by financing activities from continuing operations	16,658		19,536
Cash flows from discontinued operations:	'		'
Net cash used in operating activities of discontinued operations	-144		-1,279
Net cash provided by (used in) investing activities of discontinued operations	1,500		-1,260
Net cash provided by (used in) discontinued operations	1,356		-2,539
Effect of exchange rate changes on cash	0		127
Net increase in cash and cash equivalents	5,489		9,426
Cash and cash equivalents, beginning of period	15,130	[1]	7,435
Cash and cash equivalents, end of period	20,619		16,861
Supplemental disclosure of cash flow information:	'		'
Cash paid for interest	189		223
Non-cash investing and financing activities:	'		'
Issuance of 486,923 shares of common stock upon conversion of convertible note	1,737		0
Receivable from buyer upon sale of BQ Kits	51		0
TopoTarget	'		'
Non-cash investing and financing activities:	'		'
Issuance of common stock for acquisition	1,543		0
Finesco	'		'
Non-cash investing and financing activities:	'		'
Issuance of common stock for acquisition	0		8,556
PediatRx Inc.	'		'
Non-cash investing and financing activities:	'		'
Issuance of 373,134 shares of common stock to PediatRx Inc. for co-promote agreement	$0		$1,000
[1]	The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Issuance of shares of common stock upon conversion of convertible note	486,923	0
TopoTarget	'	'
Issuance of common stock upon acquisition, shares	688,717	0
Finesco	'	'
Issuance of common stock upon acquisition, shares	0	2,592,592
PediatRx Inc.	'	'
Issuance of common stock to PediatRx Inc. for co-promote agreement, shares	0	373,134

Organization_Basis_of_Presenta

Organization, Basis of Presentation and Liquidity	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
ORGANIZATION, BASIS OF PRESENTATION AND LIQUIDITY	'
	ORGANIZATION, BASIS OF PRESENTATION AND LIQUIDITY
	Organization
	Apricus Biosciences, Inc. and Subsidiaries (“Apricus Bio” or the “Company”) was incorporated in Nevada in 1987. The Company has operated in the pharmaceutical industry since 1995, primarily focused on product development and commercialization in the area of sexual health. The Company’s proprietary drug delivery technology is called NexACT® and the Company has one approved drug using the NexACT® delivery system, Vitaros®, which is approved in Canada and in Europe through the European Decentralized Procedure as a cold-chain product for the treatment of erectile dysfunction (“ED”).  The Company has a second generation Vitaros® product (“Room Temperature Vitaros®") in development, which is a proprietary stabilized dosage formulation that allows the product to be stored at room temperature conditions. Also in the area of sexual health is the Company’s Femprox® product candidate for female sexual interest / arousal disorder (“FSIAD”).
	In July 2012, the Company accepted, by way of a share contribution, one hundred percent of all outstanding common stock of Finesco SAS, a holding company incorporated in France (“Finesco”) and Scomedica SAS, a company incorporated in France and a wholly-owned subsidiary of Finesco (“Scomedica”). This transaction was a business acquisition under United States ("U.S.") generally accepted accounting principles ("GAAP") (See Note 3). Further, in July 2012, Finesco acquired all of the capital stock of Portalis SARL, a French company that qualifies as a French pharmaceutical sales license. The Company later changed the name and corporate structure of Portalis SARL to NexMed Pharma SAS (“NexMed Pharma”) (collectively, Finesco, Scomedica and NexMed Pharma are referred to herein as the “French Subsidiaries”). In March 2013, the French Subsidiaries entered into a bankruptcy reorganization procedure as a result of a decrease in the unit’s operating performance resulting from the then recently enacted pricing policies affecting drug reimbursement in France, the subsequent related loss or interruption of certain contract sales agreements and in this context, the Company’s decision to cease financing the French Subsidiaries. In April 2013, the French Subsidiaries entered into a judicial liquidation procedure. As a result of these actions, effective April 25, 2013, the Company no longer controlled the French Subsidiaries in accordance with consolidation guidance and as a result, the assets and liabilities of those entities were deconsolidated and the operating results are no longer included in the Company’s consolidated financial statements subsequent to April 25, 2013.
	In December 2012, the Company initiated strategic changes to its business by seeking a buyer for its U.S. oncology supportive care business, including its products Totect® and Granisol®. In March 2013, Apricus Pharmaceuticals USA, Inc. (“Apricus Pharmaceuticals”), the Company’s wholly-owned subsidiary, entered into an Asset Purchase Agreement (the “Biocodex Agreement”) whereby the Company sold to Biocodex, Inc. (“Biocodex”) all of the Company’s rights and certain information, property and inventory related to Totect® (See Note 4). In September 2013, the Company negotiated a settlement agreement which resulted in the extinguishment of certain contingent consideration associated with the 2011 purchase of Totect®, and in the third quarter of 2013 the Company ceased its contractual arrangements related to Granisol®.
	These actions are intended to enable the Company to increase its focus on its primary products: Vitaros® for ED, for which the Company is seeking additional regulatory approvals and potential licensing opportunities, and Femprox® for FSIAD, for which the Company is currently evaluating the potential for it as a development candidate.
	Basis of Presentation
	The consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of the Company’s management, all adjustments that are of a normal recurring nature and considered necessary for fair statement have been included in the accompanying consolidated financial statements. Certain prior year items have been reclassified to conform to the current year presentation. The consolidated financial statements (unaudited) for the interim periods are not necessarily indicative of results for the full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K as initially filed with the SEC and as amended by Form 10-K/A (Amendment No. 1) for the year ended December 31, 2012.
	Use of Estimates
	The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The Company’s most significant estimates relate to the estimated fair value of future contingent consideration related to the acquisition of TopoTarget USA, Inc. and other acquisition or disposition related activities, whether revenue recognition criteria have been met, estimated costs to complete under its research contracts, the fair value of its embedded derivatives related to the convertible notes payable, and valuation allowances for the Company’s deferred tax benefit. The Company’s actual results may differ from these estimates under different assumptions or conditions.
	Segment Information
	The internal organization used by the Company’s Chief Operating Decision Maker (“CODM”) to assess performance and allocate resources determines the basis for its reportable operating segments. The Company’s CODM is the Chief Executive Officer. Beginning in July 2013, the Company operated under only one segment, Pharmaceuticals, which designs and develops pharmaceutical products including those with its NexACT® platform. All of the Company's revenues during the three and nine months ended September 30, 2013 related to Europe and all of its long-lived assets as of September 30, 2013 related to the U.S. operations.
	Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board ("FASB") issued amendments to address the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. The amendments are effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013 (early adoption is permitted). The Company does not expect the adoption to have a material impact on the consolidated financial position and results of operations.
	In July 2013, the FASB issued an Accounting Standard Update ("ASU") that requires an unrecognized tax benefit be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward (collectively referred to as a “tax attribute carryforward”), unless the jurisdiction from which the tax attribute carryforward arose does not allow for such treatment. To the extent that a company does not have a tax attribute carryforward as of the reporting date, the unrecognized tax benefit is to be reported as a liability. The Company will adopt this ASU in the first quarter of 2014. The Company does not expect the adoption to have a material impact on the consolidated financial position and results of operations.
	Liquidity
	The accompanying consolidated financial statements have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $266.7 million as of September 30, 2013, recorded a net loss of approximately $15.6 million for the nine months ended September 30, 2013 and has principally been financed through the public offering of our common stock and other equity securities, private placements of equity securities, debt financing and up-front payments received from commercial partners for our products under development. Funds raised in recent periods include approximately $15.8 million and $18.4 million from our May 2013 and February 2012 follow-on public offerings, respectively. Additionally, the Company raised approximately $0.8 million during the nine months ended September 30, 2013 from the sale of common stock via its “at-the-market” stock selling facility and approximately $2.0 million from this facility in 2012. In March 2013, the Company completed the sale of its New Jersey Facility to a third-party resulting in net proceeds to the Company of approximately $3.6 million (See Note 5). In March 2013, the Company received $1.5 million in cash, as consideration for the sale of its Totect® assets (See Note 4). These cash generating activities should not necessarily be considered an indication of our ability to raise additional funds in any future periods due to the uncertainty associated with raising capital.
	Our cash and cash equivalents as of September 30, 2013 were approximately $20.6 million. The Company expects to require additional external financing to fund its long-term operations. Based upon our current business plan, the Company believes it has sufficient cash reserves to fund our on-going operations through 2014. The Company expects to continue to have net cash outflows from operations in 2013 as it continues to support the market approvals and partner commercialization plans for Vitaros®, further develops Room Temperature Vitaros® and evaluates its regulatory and clinical trial strategy for Femprox® . The Company expects its cash inflows during the latter part of 2013, if any, will be from licensing and milestone revenues received from existing and any potential new commercial partners for licenses granted for Vitaros®.
	Based on its recurring losses, negative cash flows from operations and working capital levels, the Company will need to raise substantial additional funds to finance its operations. If the Company is unable to maintain sufficient financial resources, including by raising additional funds when needed, its business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that the Company will be able to obtain the needed financing on reasonable terms or at all. Additionally, equity financings may have a dilutive effect on the holdings of the Company’s existing stockholders.
	As a result of the French Subsidiaries entering into judicial liquidation procedures in April 2013, the Company deconsolidated the French Subsidiaries in the second quarter of 2013. Although the Company does not expect to be liable for the unsatisfied liabilities of the French Subsidiaries in the liquidation process in France, it is possible that a French court could impose these liabilities on the Company. If that was to occur, the Company may be required to satisfy liabilities of the liquidating French Subsidiaries. If the Company were held liable for liabilities of the French Subsidiaries, then it is likely that the liquidation activities in France could have a material adverse effect on the Company’s financial condition (See Note 10).

Licensing_and_Research_and_Dev

Licensing and Research and Development Agreements	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS	'
	LICENSING AND RESEARCH AND DEVELOPMENT AGREEMENTS
	Vitaros®
	Abbott Laboratories Limited
	In January 2012, the Company entered into an exclusive license agreement with Abbott Laboratories Limited (“Abbott”), granting Abbott the exclusive rights to commercialize Vitaros® for ED in Canada. The product was approved by Health Canada in late 2010. Under the license agreement, the Company received $2.5 million in October 2012 as an up-front payment. The Company determined that the only deliverable was the license element and given no additional obligation was associated with the license, the up-front license fee of $2.5 million from Abbott was recorded as revenue in the third quarter of 2012.
	Over the term of the agreement, the Company has the right to receive an additional $13.2 million in aggregate milestone payments if all the regulatory and sales thresholds specified in the agreement are achieved, plus tiered royalty payments based on Abbott’s sales of the product in Canada.
	Bracco SpA
	On December 22, 2010, the Company entered into an exclusive license agreement with Bracco SpA (“Bracco”) for its Vitaros® product for ED. Under the terms of the license agreement, Bracco has been granted exclusive rights in Italy to commercialize and market Vitaros® under the Bracco trademark, and the Company received €0.75 million ($1.0 million) as an up-front payment during the year ended December 31, 2011, and is entitled to receive up to €4.75 million ($6.4 million as of September 30, 2013), net of withholding taxes, in regulatory and sales milestone payments. Further, over the life of the agreement, the Company is entitled to receive tiered double-digit royalties based on Bracco’s sales of the product.
	The Company concluded that the only deliverable was the license element, but $0.3 million of the $1.0 million up-front payment was contingent upon the Company receiving regulatory marketing approval for the product in Europe. Therefore, $0.7 million, net of withholding taxes, was recognized as license revenue during the year ended December 31, 2011, as there was no additional obligation associated with the license. The remaining $0.3 million was deferred until the Company received regulatory marketing approval for the product in Europe, which occurred during the second quarter of 2013. Under the license agreement, an additional regulatory milestone of approximately $0.3 million was triggered by the European regulatory approval in the second quarter of 2013 and as a result approximately $0.3 million was billed and recognized as revenue for this substantive milestone during the second quarter of 2013, for a total of approximately $0.6 million of revenue recognized during the second quarter of 2013.
	Sandoz, a division of Novartis
	In February 2012, the Company entered into an exclusive license agreement with Sandoz, a division of Novartis (“Sandoz”) for Sandoz to market Vitaros® for the treatment of ED in Germany. Under the license agreement, the Company has the right to receive up to approximately €22 million ($29.7 million as of September 30, 2013) in up-front and aggregate milestone payments if all the regulatory and sales thresholds specified in the agreement are achieved, as well as tiered double-digit royalties on net sales by Sandoz in Germany. Based on the results of the Company’s analysis, the Company concluded that the only deliverable was the license element and given no additional obligation was associated with the license, the up-front license fee of $0.7 million, net of withholding taxes, from Sandoz was recorded as revenue in the first quarter of 2012.
	Takeda Pharmaceuticals International GmbH
	In September 2012, the Company entered into an exclusive license agreement with Takeda Pharmaceuticals International GmbH (“Takeda”) to market the Company’s Vitaros® drug for the treatment of ED in the United Kingdom. Under the license agreement, the Company has the right to receive up to €34.65 million ($46.8 million as of September 30, 2013) in up-front license fees and aggregate milestone payments if all the regulatory and sales thresholds specified in the agreement are achieved, plus low double-digit royalty payments. The agreement with Takeda includes two deliverables: the granting of a license and manufacturing, with related product supply. In accordance with the accounting guidance on revenue recognition for multiple-element agreements, the product supply element of the agreement meets the criteria for separation. Therefore, it will be treated as a single unit of accounting and, accordingly, the supply price of product shipped to Takeda will be recognized as revenue for the supply element when earned. Given no additional obligation was associated with the license element, the up-front license fee of $1.0 million from Takeda was recognized as revenue in the third quarter of 2012.
	Warner Chilcott UK Limited
	In February 2012, the Company entered into an Alprostadil Cream and Placebo Clinical Supply Agreement (the “Supply Agreement”), as amended, with Warner Chilcott UK Limited (“Warner Chilcott UK”), a subsidiary of Actavis pls. Under the Supply Agreement, the Company is entitled to receive approximately $0.3 million in exchange for Vitaros® ordered by Warner Chilcott UK. During the second half of 2012, the Company received additional work orders from Warner Chilcott UK under the Supply Agreement, ordering additional quantities of the Vitaros® product and requesting that certain testing procedures be performed by the Company. The associated aggregate amount of the purchase orders received in 2012 from Warner Chilcott UK was approximately $1.2 million and reflects the value of the products to be delivered and certain testing procedures to be performed.
	The Company determined that the agreement with Warner Chilcott UK includes two deliverables: certain contract services and product supply. The product supply element of the agreement was treated as a single unit of accounting and, accordingly, the supply price of product shipped to Warner Chilcott UK was recognized as revenue for the supply element when earned. The contract services element of the agreement is treated as a separate unit of accounting and revenue is recognized using the proportional performance method over the period in which the contract services are performed. During the nine months ended September 30, 2013, the Company recognized contract service revenue of $0.6 million. Since the inception of the study, the Company has recognized a total of $1.1 million in contract service revenue.

French_Business_Combination_an

French Business Combination and Deconsolidation	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
FRENCH BUSINESS COMBINATION AND DECONSOLIDATION	'
	FRENCH BUSINESS COMBINATION AND DECONSOLIDATION
	Ownership of the French Subsidiaries
	On July 12, 2012, the Company entered into an agreement under which it accepted, by way of a share contribution, one hundred percent of all outstanding common stock of Finesco and its wholly-owned subsidiary, Scomedica, which became a wholly-owned indirect subsidiary of the Company in a transaction accounted for under the acquisition method of accounting for business combinations under the business combination guidance. Further, in July 2012, Finesco acquired all of the capital stock of Portalis SARL, later renamed NexMed Pharma. Accordingly, the assets acquired and liabilities assumed of the French Subsidiaries were recorded as of the transaction date at their respective fair values and are included in the consolidated balance sheet as of December 31, 2012.
	On March 28, 2013, the Commercial Court of Versailles, France opened a bankruptcy reorganization of the French Subsidiaries following a declaration of insolvency by their legal representative. On April 25, 2013, the French Subsidiaries entered into a judicial liquidation procedure. As a result of the conversion of the bankruptcy reorganization into a liquidation process, the Company deconsolidated the three French Subsidiaries from the Company’s financial statements as of April 25, 2013, the date that the Company no longer controlled the French Subsidiaries in accordance with the consolidation guidance. The operations of the French Subsidiaries from January 1, 2013 through April 25, 2013 are included in the continuing operations of the Company up to the date of deconsolidation. The Company believes that the estimates made as of April 25, 2013 are reasonable and does not believe that any differences in these estimates would have a material impact on the financial condition or results of operations of the Company. Through September 30, 2013, there have been no changes to these estimates.
	As a result of the deconsolidation, the Company recorded a non-cash net benefit of $0.6 million during the second quarter of 2013, which was a result of other comprehensive income being adjusted into income and reflected as deconsolidation of French Subsidiaries on the consolidated income statement. In addition, the Company has recorded a liability of $2.8 million as of September 30, 2013 for the amount of the net deconsolidation liabilities associated with the French Subsidiaries. Although the Company does not expect to be liable for the unsatisfied liabilities of the French Subsidiaries in the liquidation process in France, it is possible that a French court could impose these liabilities on the Company. If that was to occur, the Company may be required to satisfy liabilities of the liquidating French Subsidiaries and therefore, the Company has not recorded a benefit from the deconsolidation. Any resulting gain or loss from the deconsolidation will be recorded when realized on the date the Company has no further obligations associated with this matter.

Other_Acquisitions_and_Disposi

Other Acquisitions and Dispositions	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
OTHER ACQUISITIONS AND DISPOSITIONS	'
	OTHER AQUISITIONS AND DISPOSITIONS
	Apricus Pharmaceuticals
	TopoTarget
	In April 2013, the Company delivered 148,441 shares of common stock representing $0.3 million of holdback consideration owed to TopoTarget A/S. In addition, approximately $0.1 million was recorded as other expense as a result of a change in stock price between the agreement date and the date the shares were issued.
	Following the sale of the Totect® assets, the liabilities related to Totect® were reclassified to continuing operations. In September 2013, the Company and TopoTarget A/S negotiated a settlement agreement which resulted in the extinguishment of the contingent consideration associated with milestone stock payments and all other obligations set forth in the purchase agreement, in exchange for 540,276 shares of Apricus common stock, valued at approximately $1.2 million at the date of issuance. The shares are subject to sale by Topotarget A/S in accordance with a stock selling plan. To the extent that the shares, when sold by TopoTarget A/S, have an aggregate value of less than $1.1 million, the Company would be required to provide additional consideration to TopoTarget A/S in the form of additional shares in an amount equal to the shortfall. The liability associated with the potential additional shares was valued using a Monte Carlo valuation model as of the date of the settlement agreement, with the following inputs: stock price on the date of issuance ($2.02), 63% volatility, a term of 0.41 years and a risk-free interest rate of 0.04%. These unobservable inputs represent a Level 3 measurement within the fair value hierarchy.
	During the three month period ended September 30, 2013, the Company recorded a non-cash gain of $0.5 million in its continuing operations for the difference between the contingent consideration of $1.7 million relieved from liabilities and the $1.2 million of common stock provided in accordance with the settlement agreement. In addition, the Company recorded a non-cash charge for the fair value of the potential additional shares of approximately $0.2 million, which has been recorded as a short-term derivative liability on the Company's consolidated balance sheet and as other expense in the Company's statement of operations for the three and nine months ended September 30, 2013.
	Sale of Totect® Assets
	On March 26, 2013, the Company entered into and closed the Biocodex Agreement whereby the Company agreed to sell to Biocodex all of the Company’s rights and certain information, property and inventory related to Totect® (the “Assets”) in exchange for $1.5 million in cash at the closing date plus the right to receive double-digit, tiered, decreasing royalties based on Biocodex’s net sales over the next three years (the “Transaction”).
	The royalty payments are based on a percentage of net sales beginning on March 26, 2013. The Company evaluated the potential and estimated future earn-out payments prescribed by the future royalty arrangement and performed certain due diligence on Biocodex’s operations, concluding that it was unable to determine the amount, timing or certainty of its ability to receive future royalty payments from Biocodex associated with the future sales of Totect® and accordingly, has not recorded an earn-out receivable associated with the Biocodex Agreement.
	A summary of the assets sold in conjunction with the sale of the Assets as of March 26, 2013 is as follows (in thousands):
	Current assets, including inventory, prepaid expenses	$	960
	Fixed assets, net of depreciation	63
	Technology license, net of accumulated amortization	1,467
	Trade name license, net of accumulated amortization	411
		$	2,901
	The Company retained all liabilities arising in connection with the manufacture or commercialization of Totect® by the Company prior to the closing date of the Transaction.
	The Company recorded a loss of $1.4 million in the first quarter of 2013 related to the sale of the Assets which represented the difference between the book value of the assets sold and the $1.5 million in cash consideration received. The Company will recognize any future earnings related to the receipt of royalties from Biocodex in the reporting period when earned as a recovery of the loss within discontinued operations. This loss and any future earnings will be presented in discontinued operations.
	Granisol®
	In February 2012, the Company entered into the following agreements with PediatRx Inc. (“PediatRx”): (1) a Co-Promotion Agreement in the U.S. for Granisol®, an oral liquid granisetron based anti-emetic product (the “Co-Promotion Agreement”), (2) an assignment of PediatRx’s rights under its Co-Promotion Agreement with Bi-Coastal Pharmaceuticals, Inc. for Aquoral®, for dry mouth or Xerostomia in the U.S. and (3) an Asset Purchase Agreement for Granisol® outside of the U.S. (the “Sale Agreement”). As consideration for entering into the agreements, the Company paid PediatRx $0.3 million up-front and agreed to pay PediatRx a percentage royalty on the Company’s net operating income related to sales of Granisol® in the U.S. The majority of the $0.3 million was related to the Co-Promotion Agreement and therefore recorded as an intangible asset in the Pharmaceuticals segment with an estimated useful life of ten years, equal to the life of the agreement. The remaining portion, which was recorded as research and development expense, related to intellectual property for a particular research and development project that did not reach technological feasibility in the territories covered by the license and that has no alternative future use.
	On June 27, 2012, the Company entered into a termination agreement with PediatRx, Inc., ending discussions regarding the potential merger transaction whereby the Company would have acquired PediatRx (the “Merger”). In January 2012, the Company had entered into a term sheet for the acquisition of PediatRx, which included an additional payment by the Company to PediatRx of $1.0 million payable in Company common stock if the Company elected not to pursue the Merger, subject to certain conditions. On June 27, 2012, triggered by the termination agreement and in settlement of the $1.0 million payable, the Company issued and delivered to PediatRx 373,134 shares of common stock, which were valued at a price of $2.68 per share. The $1.0 million dollar payment was considered part of the cost of the Co-Promotion Agreement and was recorded as an intangible asset in the Pharmaceuticals segment, with an estimated useful life of ten years, equal to the life of the agreement. While the Merger itself was terminated, the Company retained the ex-U.S. worldwide rights to Granisol® under the Sale Agreement and the U.S. co-promotion rights to Granisol® under the Co-Promotion Agreement.
	In June 2013, after seeking strategic alternatives for its U.S. oncology supportive care business, the Company determined that it would no longer pursue a buyer for its sales promotional interest in the Granisol® product and provided a notice of termination to PediatRx under the Co-Promotion Agreement, which was finalized in August 2013. There is no remaining inventory or distribution activity related to Granisol® at this time.
	The liabilities related to Apricus Pharmaceuticals, which have been reclassified to continuing operations as of the date of the sale, were $0.5 million as of September 30, 2013.
	BQ Kits
	The Company had a small segment of research-use-only Elisa Kits and Rapid Tests across a range of targets. The business was not core to the Company’s current strategy focused on the development and commercialization of products associated with male and female sexual health and in June 2013, management determined that the segment would be offered for sale to qualified buyers and initiated a sale process. Accordingly, the operating results of the BQ Kits, Inc. ("BQ Kits") business were included in discontinued operations for the three and nine months ended September 30, 2013 and 2012.
	In July 2013, the Company sold BQ Kits to an unrelated third-party for a total gain on sale of approximately $0.2 million, which was reflected in discontinued operations in the third quarter financial results of the Company.
	Discontinued Operations
	The Company had no assets or liabilities within discontinued operations (Apricus Pharmaceuticals and BQ Kits) as of September 30, 2013. The carrying amounts of its assets and liabilities of its discontinued operations as of December 31, 2012 are as follows (in thousands):
	Inventories	$	292
	Prepaid expenses and other current assets	533
	Current assets of discontinued operations	825
	Fixed assets, net	40
	Intangible assets, net	1,877
	Other long-term assets	23
	Noncurrent assets of discontinued operations	1,940
	Total assets of discontinued operations	$	2,765
	Trade accounts payable	$	708
	Accrued expenses	1,087
	Deferred revenue	243
	Contingent consideration	1,328
	Provision for replacement inventory	170
	Current liabilities of discontinued operations	3,536
	Contingent consideration	420
	Provision for replacement inventory	27
	Noncurrent liabilities of discontinued operations	447
	Total liabilities of discontinued operations	$	3,983
	The operating results of the Company’s discontinued operations are as follows (in thousands):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Product sales	$	58		$	257		$	432		$	484
	Cost of goods sold	23			(114		)	(177		)	(274		)
	Operating expenses	(65		)	(913		)	(382		)	(2,407		)
	Other income	—			197			—			4
	Gain (loss) on sale of assets	198			—			(1,231		)	—
	Income (loss) from discontinued operations	$	214		$	(573	)	$	(1,358	)	$	(2,193	)

Other_Financial_Information

Other Financial Information	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
OTHER FINANCIAL INFORMATION	'
	OTHER FINANCIAL INFORMATION
	Inventory
	Inventory as of September 30, 2013 was $0.3 million and consisted of raw material of $0.2 million and work-in-progress of $0.1 million. The Company had no inventory balance as of December 31, 2012.
	Property and Equipment
	Property and equipment are comprised of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Leasehold improvements	$	20		$	130
	Machinery and equipment	135			126
	Capital lease equipment	76			76
	Computer software	134			17
	Furniture and fixtures	36			31
	Equipment in process	300			318
	Total property and equipment	701			698
	Less: accumulated depreciation and amortization	(152		)	(97		)
	Property and equipment, net	$	549		$	601
	Depreciation expense totaled $0.02 million and $0.06 million for the three and nine months ended September 30, 2013, respectively. Depreciation expense totaled $0.01 million and $0.19 million for the three and nine months ended September 30, 2012, respectively.
	Sale of Property
	In August 2012, the Company decided to sell its facility in East Windsor, New Jersey and as a result, during the year-ended December 31, 2012, the land, building and machinery associated with the facility were reclassified to property held for sale. Monthly depreciation and amortization previously attributed to the assets was ceased. On December 28, 2012, an agreement was signed to sell the facility for a total of $4.1 million. The Company performed a review for impairment of the facility based on this offer price, less the estimated selling costs of $0.5 million, and recorded an impairment charge of approximately $0.5 million in general and administrative expenses in 2012. The property was leased to a tenant under a long-term lease.
	On March 11, 2013, the Company sold the building to an unrelated third party buyer for gross cash proceeds of $4.1 million. The rental income received from the tenant prior to the sale was recognized as other income in continuing operations during the nine months ended September 30, 2013.
	Pursuant to the building sale agreement, $0.2 million is restricted cash held in escrow for environmental remediation services to be performed and for taxes, both of which are the obligation of the Company. The Company has recorded a liability for the environmental remediation as well as tax liabilities, both of which are included in accrued liabilities. These liabilities represent the best estimate of the fair value of the total obligations and are expected to be satisfied within the current year and are therefore classified as current restricted cash and current liabilities, respectively.
	Accrued Expenses
	Accrued expenses are comprised of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Consulting fees	$	67		$	388
	Professional fees	747			286
	Outside research and development services	671			564
	Other	695			244
	Social and VAT taxes	—			359
		$	2,180		$	1,841

Deferred_Compensation

Deferred Compensation	9 Months Ended
	Sep. 30, 2013
Compensation and Retirement Disclosure [Abstract]	'
DEFERRED COMPENSATION	'
	DEFERRED COMPENSATION
	On December 28, 2012, the Company entered into a Separation Agreement and Mutual Release (the “Separation Agreement”) with Bassam Damaj, Ph.D. (“Dr. Damaj”). Dr. Damaj served as the Company’s President and Chief Executive Officer until November 2012, at which time he tendered his resignation as an officer and director of the Company. Pursuant to the Separation Agreement, the Company agreed to pay Dr. Damaj a total of $0.5 million in cash, of which $0.1 million was paid in 2012 and $0.4 million was paid during the first seven months of 2013. During the quarter ended March 31, 2013, 46,667 shares were issued to Dr. Damaj, in accordance with the Separation Agreement. In addition, 300,000 stock options were out-of-the-money and expired at the end of the ninety day exercise period, which occurred in February 2013. In 2002, the Company entered into an employment agreement with Y. Joseph Mo, Ph.D., pursuant to which Dr. Mo served as the Company’s Chief Executive Officer and President. Under the employment agreement, Dr. Mo was entitled to severance, payable monthly for 180 months, upon termination of his employment. Dr. Mo’s employment was terminated in December 2005. The Company has recorded deferred severance compensation, pursuant to the terms of the agreement, of $0.7 million and $0.8 million as of September 30, 2013 and December 31, 2012, respectively.
	Total deferred compensation related to executive compensation severance included in the consolidated balance sheet as of September 30, 2013 and December 31, 2012 was $0.7 million and $2.1 million, respectively.

Convertible_Notes_Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
CONVERTIBLE NOTES PAYABLE	'
	CONVERTIBLE NOTES PAYABLE
	On December 7, 2012, the Company issued convertible notes (the “2012 Convertible Notes”). The 2012 Convertible Notes are, at the holders’ option, redeemable in cash upon maturity at December 31, 2014 or convertible into shares of common stock at a current conversion price of $2.58 per share, which price is subject to adjustment upon certain dilutive issuances of common stock. The 2012 Convertible Notes bear interest at 7% per annum, which is payable quarterly at the Company’s option in cash or, if the Company’s net cash balance is less than $3.0 million at the time of payment, in shares of common stock. If paid in shares of common stock, then the price of the stock issued is determined at 95% of the five-day weighted average of the market price of the common stock prior to the time of payment.
	The fair value of the 2012 Convertible Notes was determined on the amendment date based on a discounted cash flow model using a risk adjusted annual interest rate of approximately 16%, which represents a Level 3 measurement within the fair value hierarchy given that this is an unobservable input. The fair value of these notes as of September 30, 2013 approximates the book value. The holders have the option to redeem $1.5 million of the principal on the 2012 Convertible Notes on April 1, 2014 and therefore that portion has been classified as a short term liability within the consolidated balance sheet.
	The 2012 Convertible Notes have an anti-dilution provision that results in an embedded conversion feature that has been accounted for as a derivative. The Company valued the derivative as of December 31, 2012 using a Black-Scholes valuation model on the issuance date using the following inputs: stock price on the day of issuance ($1.93), 70% volatility, a 2 year term and a risk-free interest rate of 0.25%. These unobservable inputs represent a Level 3 measurement within the fair value hierarchy. The estimated fair value of the conversion feature is revalued on a quarterly basis and any resulting increases or decreases in the estimated fair value are recorded as adjustments to other income (expense). The fair value as of September 30, 2013 was revalued using the following inputs: stock price of $2.09, 60% volatility, a 1.25 year term and a risk-free interest rate of 0.25% as of September 30, 2013. The estimated fair value of the conversion feature as of September 30, 2013 and December 31, 2012 was $0.3 million and $0.9 million, respectively, which has been recorded as a derivative liability in the consolidated balance sheets.
	During the nine months ended September 30, 2013, the Company issued 486,923 common shares upon the conversion of $1.25 million of the principal balance of the 2012 Convertible Notes into common stock. $0.7 million of the derivative liability was re-classified to additional paid in capital upon conversion, and $0.2 million of the debt discount was credited to additional paid in capital.
	The Company’s convertible notes payable balance as of September 30, 2013 and December 31, 2012 consisted of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Convertible notes payable	$	4,000		$	4,000
	Less: conversions to common stock	(1,250		)	—
		2,750			4,000
	Less: unamortized debt discount	(207		)	(587		)
		$	2,543		$	3,413
	Current portion, net of discount of $59	$	1,441		$	—
	Long term portion, net of discount of $148 as of September 30, 2013 and $587 as of December 31, 2012	1,102			3,413
		$	2,543		$	3,413
	The Company recognized interest expense related to its convertible notes payable of $0.1 million during each of the three months ended September 30, 2013 and 2012. The Company recognized interest expense of $0.4 million and $0.2 million during the nine months ended September 30, 2013 and 2012, respectively.

Stockholders_Equity

Stockholders Equity	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
STOCKHOLDERS' EQUITY	'
	STOCKHOLDERS' EQUITY
	Preferred Stock
	The Company is authorized to issue 10.0 million shares of preferred stock, par value $0.001, of which 1.0 million shares are designated as Series A Junior Participating Preferred Stock, 800 are designated as Series B 8% Cumulative Convertible Preferred Stock, 600 are designated as Series C 6% Cumulative Convertible Preferred Stock and 50,000 have been designated as Series D Junior Participating Cumulative Preferred Stock. No shares of preferred stock were outstanding as of September 30, 2013 or December 31, 2012.
	Common Stock Offerings
	The Offering Agreement
	On December 30, 2011, the Company entered into a Controlled Equity Offering Agreement (the “Offering Agreement”) with Ascendiant Capital Markets, LLC (“Ascendiant”). Pursuant to the Offering Agreement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $20.0 million, from time to time through Ascendiant. The sales of the common stock under the Offering Agreement will be made in “at the market” offerings as defined in Rule 415 of the Securities Act of 1933 (the “Securities Act”), including sales made directly on the NASDAQ Capital Market, on any other existing trading market for the Shares or to or through a market maker. Our at-the-market common stock selling facility may be terminated by either party by giving proper written notice. In April 2013, the Company amended the Offering Agreement primarily to change the effective shelf registration statement on Form S-3 associated with the shares to be sold under the “at-the-market offerings.” As a result of the amendment, Registration Statement No. 333-178832 is now associated with the at-the-market facility.
	Prior to March 31, 2013, the shares sold in the offering were issued pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-165960) previously filed with the SEC in accordance with the provisions of the Securities Act, as supplemented by a prospectus supplement dated December 30, 2011, which the Company filed with the SEC pursuant to Rule 424(b)-(5) under the Securities Act. During 2012, the Company sold an aggregate of 515,329 shares of common stock under the Offering Agreement at a weighted average sales price of approximately $3.87 per share, resulting in offering proceeds of approximately $2.0 million, net of sales commissions. During the first half of 2013, the Company sold an aggregate of 312,450 shares of common stock under the Offering Agreement at a weighted average sales price of approximately $2.63 per share, resulting in offering proceeds of approximately $0.8 million, net of sales commissions of $0.03 million. There were no shares sold under the Offering Agreement during the third quarter of 2013.
	2012 Units
	On February 14, 2012, the Company offered and sold 4,938,272 units (“2012 Units”) in a follow-on public offering of securities with each 2012 Unit consisting of one share of common stock, $0.001 par value per share of the Company and one warrant to purchase 0.50 shares of Common Stock at a price of $5.25 per full warrant share. The 2012 Units were offered at a public offering price of $4.05 per 2012 Unit. The underwriters purchased the 2012 Units from the Company at a price of $3.807 per 2012 Unit, which represented a 6.0% discount to the public offering price. The warrants were exercisable immediately upon issuance and will expire five years from the date of issuance. The net proceeds to the Company from this offering were approximately $18.4 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company. In accordance with the equity guidance, the warrants’ fair value of $3.7 million was determined on the date of grant using the Black-Scholes model with the following assumptions: risk free interest rate of 1.0%, volatility of 70.0%, a 5.0 year term and no dividend yield. These warrants were recorded as a component of stockholders’ equity with an equal offsetting amount to stockholders’ equity because the value of the warrants was considered a financing cost given the warrants did not meet the liability classification criteria. As of September 30, 2013, no warrants that were issued as part of the 2012 Unit offering have been exercised.
	2013 Units
	On May 29, 2013, the Company offered and sold 6,000,000 units (“2013 Units”) in a follow-on public offering of securities with each 2013 Unit consisting of one share of common stock, $0.001 par value per share of the Company and one warrant to purchase 0.5 shares of Common Stock at a price of $3.40 per full warrant share. The 2013 Units were offered at a public offering price of $2.85 per 2013 Unit. The underwriters purchased the 2013 Units from the Company at a price of $2.679 per 2013 Unit, which represented a 6% discount to the public offering price. The warrants were exercisable immediately upon issuance and will expire five years from the date of issuance. The net proceeds to the Company from this offering were approximately $15.8 million after deducting underwriting discounts, commissions and other offering expenses payable by the Company. In accordance with the equity guidance, the warrants’ fair value of $3.3 million was determined on the date of grant using the Black-Scholes model with the following assumptions: risk free interest rate of 1.0%, volatility of 70%, a 5 year term and no dividend yield. These warrants were recorded as a component of stockholders’ equity with an equal offsetting amount to stockholders’ equity. The value of the warrants was considered a financing cost because the warrants did not meet the liability classification criteria. No warrants that were issued as part of the 2013 Unit offering have been exercised in 2013.
	Warrants
	A summary of warrant activity during the nine months ended September 30, 2013 is as follows:
		Common Shares		Weighted		Weighted
		Issuable upon		Average		Average
		Exercise		Exercise		Remaining
				Price		Contractual
						Life (in years)
	Outstanding at December 31, 2012	3,205,492		$	4.56	3.8
	Issued	3,000,000		3.4
	Exercised	(20,000	)	2.27
	Cancelled	—		—
	Outstanding at September 30, 2013	6,185,492		4.01		3.8
	Exercisable at September 30, 2013	6,185,492		$	4.01	3.8
	On February 14, 2012, the Company issued 2,469,136 warrants as part of the sale of common stock in a follow-on public offering of securities. The warrants have an exercise price of $5.25 per share of common stock, were exercisable immediately upon issuance and will expire five years from the date of issuance.
	On May 29, 2013, the Company issued 3,000,000 warrants as part of the sale of common stock in a follow-on public offering of securities. The warrants have an exercise price of $3.40 per share of common stock, were exercisable immediately upon issuance and will expire five years from the date of issuance.

Equity_Compensation_Plans

Equity Compensation Plans	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
EQUITY COMPENSATION PLANS	'
	EQUITY COMPENSATION PLANS
	As of September 30, 2013, the Company had two share-based compensation plans that provided for awards to acquire shares of its common stock. In March 2012, the Company’s stockholders approved the 2012 Stock Long Term Incentive Plan (the “2012 Plan”), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights, as well as certain cash awards. A total of 3.0 million common shares have been authorized for issuance under the 2012 Plan, which includes 1.0 million common shares authorized in May of 2013 in accordance with the evergreen provisions of the 2012 Plan. The NexMed, Inc. 2006 Stock Incentive Plan (“the 2006 Plan”) includes 3.8 million authorized shares.
	The Company currently grants stock options and restricted compensatory stock under its 2012 Plan. Options granted generally vest over a period of one to four years and have a maximum term of 10 years from the date of grant. As of September 30, 2013, an aggregate of 6.8 million shares of common stock are authorized under the Company’s equity compensation plans, of which 3.0 million common shares are available for future grants.
	Stock Options
	A summary of stock option activity during the nine months ended September 30, 2013 is as follows:
		Number of		Weighted		Weighted	Total
		Shares		Average		Average Remaining	Aggregate
				Exercise		Contractual	Intrinsic
				Price		Life (in years)	Value
	Outstanding at December 31, 2012	2,213,916		$	3.71	8.9	$	—
	Granted	1,253,771		2.46
	Exercised	—		—
	Cancelled	(834,752	)	3.48
	Outstanding at September 30, 2013	2,632,935		$	3.19	7.5	$	11,525
	Vested or expected to vest at September 30, 2013	2,562,899		$	3.19	7.5	$	11,218
	Exercisable at September 30, 2013	1,027,577		$	4.07	4.9	$	3,275
	The weighted average grant date fair value of options granted during the nine months ended September 30, 2013, was approximately $1.55 per share.

Litigation

Litigation	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
LITIGATION	'
	LITIGATION
	The Company is a party to the following litigation and may also be involved in other litigation arising in the ordinary course of business from time to time. The Company intends to vigorously defend its interests in these matters. The Company expects that the resolution of these matters will not have a material adverse effect on its business, financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.
	Versailles Civil Court Summons
	On April 25, 2013, the French Subsidiaries entered into a judicial liquidation procedure as a result of a decrease in the unit’s operating performance resulting from recently enacted pricing policies affecting drug reimbursement in France, the subsequent related loss or interruption of certain contract sales agreements and in this context, the Company’s decision to cease financing its French Subsidiaries.
	In June of 2013, the Versailles Civil Court authorized the French Works Council (which represents individuals previously employed by the French Subsidiaries) to deliver a writ of summons to the Company as the parent company for a hearing in the Versailles Civil Court. In the summons, it is claimed that the Company was the co-employer of the individuals working for Scomedica and that, as such, is liable for the financing of a job protection plan. The summons seeks €4.1 million ($5.5 million as of September 30, 2013) from the Company. A hearing has been scheduled for November 2013 by the Versailles Civil Court.
	The Company believes that it has adequate defenses and will vigorously defend itself in the matter. The Company has not recorded a loss accrual related to the French Works Council claim as of September 30, 2013 as any possible loss or range of loss could not be reasonably estimated at that time. There can be no assurances as to the final outcome of this matter.

Organization_Basis_of_Presenta1

Organization, Basis of Presentation and Liquidity (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of the Company’s management, all adjustments that are of a normal recurring nature and considered necessary for fair statement have been included in the accompanying consolidated financial statements. Certain prior year items have been reclassified to conform to the current year presentation. The consolidated financial statements (unaudited) for the interim periods are not necessarily indicative of results for the full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K as initially filed with the SEC and as amended by Form 10-K/A (Amendment No. 1) for the year ended December 31, 2012.
Use of Estimates	'
	Use of Estimates
	The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The Company’s most significant estimates relate to the estimated fair value of future contingent consideration related to the acquisition of TopoTarget USA, Inc. and other acquisition or disposition related activities, whether revenue recognition criteria have been met, estimated costs to complete under its research contracts, the fair value of its embedded derivatives related to the convertible notes payable, and valuation allowances for the Company’s deferred tax benefit. The Company’s actual results may differ from these estimates under different assumptions or conditions.
Segment Information	'
	Segment Information
	The internal organization used by the Company’s Chief Operating Decision Maker (“CODM”) to assess performance and allocate resources determines the basis for its reportable operating segments. The Company’s CODM is the Chief Executive Officer. Beginning in July 2013, the Company operated under only one segment, Pharmaceuticals, which designs and develops pharmaceutical products including those with its NexACT® platform. All of the Company's revenues during the three and nine months ended September 30, 2013 related to Europe and all of its long-lived assets as of September 30, 2013 related to the U.S. operations.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board ("FASB") issued amendments to address the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. The amendments are effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013 (early adoption is permitted). The Company does not expect the adoption to have a material impact on the consolidated financial position and results of operations.
	In July 2013, the FASB issued an Accounting Standard Update ("ASU") that requires an unrecognized tax benefit be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward (collectively referred to as a “tax attribute carryforward”), unless the jurisdiction from which the tax attribute carryforward arose does not allow for such treatment. To the extent that a company does not have a tax attribute carryforward as of the reporting date, the unrecognized tax benefit is to be reported as a liability. The Company will adopt this ASU in the first quarter of 2014. The Company does not expect the adoption to have a material impact on the consolidated financial position and results of operations.
Liquidity	'
	Liquidity
	The accompanying consolidated financial statements have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $266.7 million as of September 30, 2013, recorded a net loss of approximately $15.6 million for the nine months ended September 30, 2013 and has principally been financed through the public offering of our common stock and other equity securities, private placements of equity securities, debt financing and up-front payments received from commercial partners for our products under development. Funds raised in recent periods include approximately $15.8 million and $18.4 million from our May 2013 and February 2012 follow-on public offerings, respectively. Additionally, the Company raised approximately $0.8 million during the nine months ended September 30, 2013 from the sale of common stock via its “at-the-market” stock selling facility and approximately $2.0 million from this facility in 2012. In March 2013, the Company completed the sale of its New Jersey Facility to a third-party resulting in net proceeds to the Company of approximately $3.6 million (See Note 5). In March 2013, the Company received $1.5 million in cash, as consideration for the sale of its Totect® assets (See Note 4). These cash generating activities should not necessarily be considered an indication of our ability to raise additional funds in any future periods due to the uncertainty associated with raising capital.
	Our cash and cash equivalents as of September 30, 2013 were approximately $20.6 million. The Company expects to require additional external financing to fund its long-term operations. Based upon our current business plan, the Company believes it has sufficient cash reserves to fund our on-going operations through 2014. The Company expects to continue to have net cash outflows from operations in 2013 as it continues to support the market approvals and partner commercialization plans for Vitaros®, further develops Room Temperature Vitaros® and evaluates its regulatory and clinical trial strategy for Femprox® . The Company expects its cash inflows during the latter part of 2013, if any, will be from licensing and milestone revenues received from existing and any potential new commercial partners for licenses granted for Vitaros®.
	Based on its recurring losses, negative cash flows from operations and working capital levels, the Company will need to raise substantial additional funds to finance its operations. If the Company is unable to maintain sufficient financial resources, including by raising additional funds when needed, its business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that the Company will be able to obtain the needed financing on reasonable terms or at all. Additionally, equity financings may have a dilutive effect on the holdings of the Company’s existing stockholders.
	As a result of the French Subsidiaries entering into judicial liquidation procedures in April 2013, the Company deconsolidated the French Subsidiaries in the second quarter of 2013. Although the Company does not expect to be liable for the unsatisfied liabilities of the French Subsidiaries in the liquidation process in France, it is possible that a French court could impose these liabilities on the Company. If that was to occur, the Company may be required to satisfy liabilities of the liquidating French Subsidiaries. If the Company were held liable for liabilities of the French Subsidiaries, then it is likely that the liquidation activities in France could have a material adverse effect on the Company’s financial condition (See Note 10).

Other_Acquisitions_and_Disposi1

Other Acquisitions and Dispositions (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Assets and Liabilities in Discontinued Operations	'
	The carrying amounts of its assets and liabilities of its discontinued operations as of December 31, 2012 are as follows (in thousands):
	Inventories	$	292
	Prepaid expenses and other current assets	533
	Current assets of discontinued operations	825
	Fixed assets, net	40
	Intangible assets, net	1,877
	Other long-term assets	23
	Noncurrent assets of discontinued operations	1,940
	Total assets of discontinued operations	$	2,765
	Trade accounts payable	$	708
	Accrued expenses	1,087
	Deferred revenue	243
	Contingent consideration	1,328
	Provision for replacement inventory	170
	Current liabilities of discontinued operations	3,536
	Contingent consideration	420
	Provision for replacement inventory	27
	Noncurrent liabilities of discontinued operations	447
	Total liabilities of discontinued operations	$	3,983
Operating Results of Discontinued Operations	'
	The operating results of the Company’s discontinued operations are as follows (in thousands):
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Product sales	$	58		$	257		$	432		$	484
	Cost of goods sold	23			(114		)	(177		)	(274		)
	Operating expenses	(65		)	(913		)	(382		)	(2,407		)
	Other income	—			197			—			4
	Gain (loss) on sale of assets	198			—			(1,231		)	—
	Income (loss) from discontinued operations	$	214		$	(573	)	$	(1,358	)	$	(2,193	)
Sale Of Assets	'
Summary of Assets and Liabilities in Discontinued Operations	'
	A summary of the assets sold in conjunction with the sale of the Assets as of March 26, 2013 is as follows (in thousands):
	Current assets, including inventory, prepaid expenses	$	960
	Fixed assets, net of depreciation	63
	Technology license, net of accumulated amortization	1,467
	Trade name license, net of accumulated amortization	411
		$	2,901

Other_Financial_Information_Ta

Other Financial Information (Tables)	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Property and Equipment	'
	Property and equipment are comprised of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Leasehold improvements	$	20		$	130
	Machinery and equipment	135			126
	Capital lease equipment	76			76
	Computer software	134			17
	Furniture and fixtures	36			31
	Equipment in process	300			318
	Total property and equipment	701			698
	Less: accumulated depreciation and amortization	(152		)	(97		)
	Property and equipment, net	$	549		$	601
Accrued Liabilities	'
	Accrued expenses are comprised of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Consulting fees	$	67		$	388
	Professional fees	747			286
	Outside research and development services	671			564
	Other	695			244
	Social and VAT taxes	—			359
		$	2,180		$	1,841

Convertible_Notes_Payable_Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Notes Payable	'
	The Company’s convertible notes payable balance as of September 30, 2013 and December 31, 2012 consisted of the following (in thousands):
		September 30,			December 31,
		2013			2012
	Convertible notes payable	$	4,000		$	4,000
	Less: conversions to common stock	(1,250		)	—
		2,750			4,000
	Less: unamortized debt discount	(207		)	(587		)
		$	2,543		$	3,413
	Current portion, net of discount of $59	$	1,441		$	—
	Long term portion, net of discount of $148 as of September 30, 2013 and $587 as of December 31, 2012	1,102			3,413
		$	2,543		$	3,413

Stockholders_Equity_Tables

Stockholders Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Summary of Warrant Activity	'
	A summary of warrant activity during the nine months ended September 30, 2013 is as follows:
		Common Shares		Weighted		Weighted
		Issuable upon		Average		Average
		Exercise		Exercise		Remaining
				Price		Contractual
						Life (in years)
	Outstanding at December 31, 2012	3,205,492		$	4.56	3.8
	Issued	3,000,000		3.4
	Exercised	(20,000	)	2.27
	Cancelled	—		—
	Outstanding at September 30, 2013	6,185,492		4.01		3.8
	Exercisable at September 30, 2013	6,185,492		$	4.01	3.8

Equity_Compensation_Plans_Tabl

Equity Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Stock Option Activity	'
	A summary of stock option activity during the nine months ended September 30, 2013 is as follows:
		Number of		Weighted		Weighted	Total
		Shares		Average		Average Remaining	Aggregate
				Exercise		Contractual	Intrinsic
				Price		Life (in years)	Value
	Outstanding at December 31, 2012	2,213,916		$	3.71	8.9	$	—
	Granted	1,253,771		2.46
	Exercised	—		—
	Cancelled	(834,752	)	3.48
	Outstanding at September 30, 2013	2,632,935		$	3.19	7.5	$	11,525
	Vested or expected to vest at September 30, 2013	2,562,899		$	3.19	7.5	$	11,218
	Exercisable at September 30, 2013	1,027,577		$	4.07	4.9	$	3,275

Organization_Basis_of_Presenta2

Organization, Basis of Presentation and Liquidity - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Jul. 12, 2012

Dec. 31, 2011

Mar. 31, 2013

31-May-13

Feb. 29, 2012

Sep. 30, 2013

Dec. 31, 2012

Jul. 31, 2012

Segment

Totect

Follow-on public offering

Follow-on public offering

At-the-market stock sales

At-the-market stock sales

Finesco

Basis of Presentation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contribution agreement, ownership interest acquired

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

100.00%

Number of operating segments

'

1

'

'

'

'

'

'

'

'

'

'

'

'

Retained earnings (accumulated deficit)

'

($266,721,000)

'

($266,721,000)

'

($251,128,000)

[1]

'

'

'

'

'

'

'

'

Net income (loss)

'

-2,985,000

-2,494,000

-15,593,000

-12,134,000

'

'

'

'

'

'

'

'

'

Proceeds from issuance of common stock

'

'

'

16,612,000

19,489,000

'

'

'

'

15,800,000

18,400,000

800,000

2,000,000

'

Proceeds from the sale of assets

3,600,000

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

Cash and cash equivalents

'

$20,619,000

$16,861,000

$20,619,000

$16,861,000

$15,130,000

[1]

'

$7,435,000

'

'

'

'

'

'

[1]

The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Licensing_and_Research_and_Dev1

Licensing and Research and Development Agreements - Additional Information (Detail)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

21 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Oct. 31, 2012

Jan. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Dec. 31, 2011

Dec. 31, 2011

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Jun. 30, 2012

Sep. 30, 2013

Feb. 29, 2012

USD ($)

USD ($)

USD ($)

USD ($)

Abbott License Agreement

Abbott License Agreement

Bracco License Agreement

Bracco License Agreement

Bracco License Agreement

Bracco License Agreement

Bracco License Agreement

Bracco License Agreement

Sandoz Agreement

Sandoz Agreement

Sandoz Agreement

Takeda Agreement

Takeda Agreement

Takeda Agreement

Warner Chilcott UK Supply Agreement

Warner Chilcott UK Supply Agreement

Warner Chilcott UK Supply Agreement

Warner Chilcott UK Supply Agreement

Warner Chilcott UK Supply Agreement

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

EUR (€)

Additional Revenue Recognized

USD ($)

Maximum

Maximum

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

Collaborative Arrangements and Non-collaborative Arrangement Transactions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from licensing agreement

'

'

'

'

$2,500,000

'

'

'

$1,000,000

€ 750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected upfront license fees and milestone payments

'

'

'

'

'

13,200,000

6,400,000

'

'

'

4,750,000

'

'

29,700,000

22,000,000

'

46,800,000

34,650,000

'

'

'

'

'

License revenue

0

3,626,000

669,000

4,299,000

'

'

'

'

700,000

'

'

600,000

700,000

'

'

1,000,000

'

'

'

'

'

'

'

Contingent revenue from up-front payment

'

'

'

'

'

'

300,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Receivable from current ordered quantity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

Total purchase order under Supply agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

Contract service revenue

$28,000

$1,269,000

$1,480,000

$1,269,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$600,000

'

$500,000

$1,100,000

'

Number of deliverables

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

2

'

French_Business_Combination_an1

French Business Combination and Deconsolidation - Additional Information (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012		Jul. 12, 2012
Business Combinations [Abstract]	'	'		'
Contribution agreement, ownership interest acquired	'	'		100.00%
Deconsolidation net benefit	($641)	'		'
Deconsolidation of French Subsidiaries	$2,846	$0	[1]	'
[1]	The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Other_Acquisitions_and_Disposi2

Other Acquisitions and Dispositions - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

Mar. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Jul. 31, 2013

Sep. 30, 2013

Apr. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jun. 30, 2012

Feb. 29, 2012

Sep. 30, 2013

Totect

Totect

BQ Kits

BQ Kits

TopoTarget

TopoTarget

TopoTarget

TopoTarget

PediatRx Inc.

PediatRx Inc.

Fair Value, Inputs, Level 3

Maximum

TopoTarget

Discontinued Operations [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition, shares of common stock issued

'

'

'

'

'

'

'

'

'

'

'

540,276

148,441

'

'

'

'

'

Business acquisition, value of common stock issued

'

'

'

'

'

'

'

'

'

'

'

$1,200,000

$300,000

$1,200,000

$1,200,000

'

'

'

Operating expenses as a result of reducing stock price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

Aggregate value floor

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

1,100,000

1,100,000

'

'

'

Stock price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.02

Fair value assumption, volatility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

63.00%

Fair value assumption, term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 months 27 days

Fair value assumption, risk-free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.04%

Gain on contract settlement

'

534,000

'

0

534,000

0

'

'

'

'

'

'

'

543,000

'

'

'

'

Contingent consideration, liability

'

'

'

'

'

'

'

'

'

'

'

1,700,000

'

1,700,000

1,700,000

'

'

'

Derivative liability

'

'

'

'

'

'

'

'

'

'

'

200,000

'

200,000

200,000

'

'

'

Proceeds from the sale of assets

3,600,000

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

Gain (loss) on disposal

'

'

1,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discontinued operations, liabilities reclassified to continuing operations

'

'

'

'

'

'

3,983,000

'

500,000

'

'

'

'

'

'

'

'

'

Up-front payment for co-promotion and sale agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

Up-front payment for co-promotion and sale agreement intangible asset

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

Co-promotion and sale agreement payment recorded as intangible asset, expected useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

Period of decreasing royalties

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

Common stock issued, merger termination agreement, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

Issuance of common stock to PediatRx Inc. for co-promote agreement, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

373,134

'

'

Common stock issued, average price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.68

'

'

Revenue from Discontinued operation

'

58,000

'

257,000

432,000

484,000

'

'

'

200,000

'

'

'

'

'

'

'

'

Net tangible assets

'

'

'

'

'

'

40,000

'

'

'

'

'

'

'

'

'

'

'

Gain on sale of segment

'

'

'

'

'

'

'

'

'

'

$200,000

'

'

'

'

'

'

'

Other_Acquisitions_and_Disposi3

Other Acquisitions and Dispositions - Summary of Assets Sold in Conjunction with Sale of Assets (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012		Mar. 26, 2013	Mar. 26, 2013	Mar. 26, 2013
In Thousands, unless otherwise specified				Sale Of Assets	Technology licenses	Trade name license
					Sale Of Assets	Sale Of Assets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'		'	'	'
Current assets, including inventory, prepaid expenses	$0	$825	[1]	$960	'	'
Fixed assets, net of depreciation	'	40		63	'	'
Intangible assets, net of accumulated amortization	'	1,877		'	1,467	411
Total	'	$2,765		$2,901	'	'
[1]	The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Other_Acquisitions_and_Disposi4

Other Acquisitions and Dispositions - Carrying Amounts of Assets and Liabilities of Discontinued Operations (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Discontinued Operations and Disposal Groups [Abstract]	'	'
Inventories	'	$292
Prepaid expenses and other current assets	'	533
Current assets of discontinued operations	0	825	[1]
Fixed assets, net	'	40
Intangible assets, net	'	1,877
Other long-term assets	'	23
Noncurrent assets of discontinued operations	0	1,940	[1]
Total assets of discontinued operations	'	2,765
Trade accounts payable	'	708
Accrued expenses	'	1,087
Deferred revenue	'	243
Contingent consideration	'	1,328
Provision for replacement inventory	'	170
Current liabilities of discontinued operations	'	3,536
Contingent consideration	'	420
Provision for replacement inventory	'	27
Noncurrent liabilities of discontinued operations	0	447	[1]
Total liabilities of discontinued operations	'	$3,983
[1]	The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Other_Acquisitions_and_Disposi5

Other Acquisitions and Dispositions - Operating Results of Discontinued Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Discontinued Operations and Disposal Groups [Abstract]	'	'	'	'
Product sales	$58	$257	$432	$484
Cost of goods sold	23	-114	-177	-274
Operating expenses	-65	-913	-382	-2,407
Other income	0	197	0	4
Gain (loss) on sale of assets	198	0	-1,231	0
Income (loss) from discontinued operations	$214	($573)	($1,358)	($2,193)

Other_Financial_Information_Ad

Other Financial Information - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Dec. 28, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'	'	'
Inventories related to continuing operation	'	$0.30	$0	$0.30	$0	$0
Raw material	'	0.2	0	0.2	0	'
Work in process	'	0.1	0	0.1	0	'
Depreciation expense	'	0.02	0.01	0.06	0.19	'
Sale of facility, price	4.1	'	'	'	'	'
Sale of facility, estimated selling cost	0.5	'	'	'	'	'
Sale of facility, impairment charge	0.5	'	'	'	'	'
Gross building sale price	'	'	'	4.1	'	'
Building sale agreement, escrow	'	$0.20	'	$0.20	'	'

Other_Financial_Information_Pr

Other Financial Information - Property and Equipment (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Abstract]	'	'
Leasehold improvements	$20	$130
Machinery and equipment	135	126
Capital lease equipment	76	76
Computer software	134	17
Furniture and fixtures	36	31
Equipment in process	300	318
Total property and equipment	701	698
Less: accumulated depreciation and amortization	-152	-97
Property and equipment, net	$549	$601	[1]
[1]	The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Other_Financial_Information_Ac

Other Financial Information - Accrued Liabilities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Consulting fees	$67	$388
Professional fees	747	286
Outside research and development services	671	564
Other	695	244
Social and VAT taxes	0	359
Accrued expenses	$2,180	$1,841	[1]
[1]	The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Deferred_Compensation_Addition

Deferred Compensation - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Mar. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
In Millions, except Share data, unless otherwise specified			Chief Executive Officer And President	Chief Executive Officer And President	Separation Agreement	Separation Agreement	Separation Agreement
						Chief Executive Officer	Chief Executive Officer
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]	'	'	'	'	'	'	'
Separation agreement, agreed payment	'	'	'	'	'	'	$0.50
Separation agreement, amount paid	'	'	'	'	'	0.4	0.1
Separation agreement, shares of common stock issued	'	'	'	'	46,667	'	'
Separation agreement, number of stock options expired	'	'	'	'	300,000	'	'
Accrued compensation balance	$0.70	$2.10	$0.70	$0.80	'	'	'
Severance payable period	'	'	'P180M	'	'	'	'
Employment termination date	'	'	'2005-12	'	'	'	'

Convertible_Notes_Payable_Addi

Convertible Notes Payable - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Debt Instrument	'	'	'	'	'
Issuance of shares of common stock upon conversion of convertible note	'	'	486,923	'	'
Principal balance of note converted into common stock	'	'	$1,250,000	'	$0
Derivative liability was re-classified as additional paid in capital upon conversion	'	'	700,000	'	'
Debt discount credited to statement of operations upon on conversion	'	'	200,000	'	'
Amortization of debt discount	100,000	100,000	400,000	200,000	'
Amended 2010 Convertible Notes	'	'	'	'	'
Debt Instrument	'	'	'	'	'
Convertible notes, conversion price	$2.58	'	$2.58	'	'
Convertible notes, coupon rate	7.00%	'	7.00%	'	'
Net cash balance threshold below which note coupon will be paid in shares of Common Stock	3,000,000	'	3,000,000	'	'
Convertible notes, coupon paid in shares of Common Stock, price per share as percentage of five-day weighted average of the market price	95.00%	'	95.00%	'	'
Period of weighted average of market price	'	'	'5 years	'	'
Convertible Note 2012	'	'	'	'	'
Debt Instrument	'	'	'	'	'
Stock price	$2.09	'	$2.09	'	'
Fair value assumption, volatility	'	'	60.00%	'	'
Fair value assumption, term	'	'	'1 year 3 months	'	'
Estimated fair value of the conversion feature	300,000	'	300,000	'	900,000
Convertible Note 2012 | Fair Value, Inputs, Level 3	'	'	'	'	'
Debt Instrument	'	'	'	'	'
Risk adjusted annual interest rate	'	'	16.00%	'	'
Convertible notes, option to redeem	'	'	$1,500,000	'	'
Convertible notes, maturity date	'	'	1-Apr-14	'	'
Stock price	'	'	'	'	$1.93
Fair value assumption, volatility	'	'	'	'	70.00%
Fair value assumption, term	'	'	'	'	'2 years
Fair value assumption, risk-free interest rate	'	'	'	'	0.25%

Convertible_Notes_Payable_Deta

Convertible Notes Payable (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]	'	'
Convertible notes payable	$4,000	$4,000
Less: conversions to common stock	-1,250	0
Long-term debt, gross	2,750	4,000
Less: unamortized debt discount	-207	-587
Convertible notes payable	2,543	3,413
Current portion, net of discount of $59	1,441	0	[1]
Long term portion, net of discount of $148 as of September 30, 2013 and $587 as of December 31, 2012	1,102	3,413	[1]
Convertible notes payable	$2,543	$3,413
[1]	The consolidated balance sheet as of December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Convertible_Notes_Payable_Pare

Convertible Notes Payable (Parenthetical) (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Convertible notes payable, current portion, discount	$59	$59
Convertible notes payable, long-term portion, discount	$148	$587

Stockholders_Equity_Additional

Stockholders Equity - Additional Information (Detail) (USD $)

9 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

29-May-13

Dec. 31, 2012

Feb. 14, 2012

31-May-13

Feb. 29, 2012

Sep. 30, 2013

Dec. 31, 2012

29-May-13

Feb. 14, 2012

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Follow-on public offering

Follow-on public offering

Follow-on public offering

Follow-on public offering

Follow-on public offering

Follow-on public offering

Follow-on public offering

Series A Junior Participating Preferred Stock

Series B 8% Cumulative Convertible Preferred Stock

Series C 6% Cumulative Convertible Preferred Stock

Series D Junior Participating Cumulative Preferred Stock

Stockholders Equity Note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock authorized

10,000,000

'

'

10,000,000

'

'

'

'

'

'

'

'

1,000,000

800

600

50,000

Preferred stock par value

$0.00

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock dividend rate

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

6.00%

'

Common stock amount issuable under the Sales Agreement

'

'

'

'

'

'

'

'

'

'

'

$20,000,000

'

'

'

'

Issuance of common stock upon exercise of warrants

'

'

'

'

'

'

'

312,450

515,329

'

'

'

'

'

'

'

Common stock issued, weighted average price per share

'

'

'

'

'

'

'

$2.63

$3.87

'

'

'

'

'

'

'

Proceeds from exercise of warrants

46,000

40,000

'

'

'

'

'

800,000

2,000,000

'

'

'

'

'

'

'

Common stock issued, sales commissions

'

'

'

'

'

'

'

30,000

'

'

'

'

'

'

'

'

Units issued in public offering

'

'

'

'

'

6,000,000

4,938,272

'

'

'

'

'

'

'

'

'

Shares of common stock per each unit sold

'

'

'

'

'

1

1

'

'

'

'

'

'

'

'

'

Common stock, par value per share

$0.00

'

'

$0.00

'

'

'

'

'

$0.00

$0.00

'

'

'

'

'

Number of stock purchase warrants per each unit sold

'

'

'

'

'

1

1

'

'

'

'

'

'

'

'

'

Shares of common stock issued by each stock purchase warrant

'

'

'

'

'

6,000,000

4,938,272

'

'

0.5

0.5

'

'

'

'

'

Warrants, exercise price

'

'

'

'

'

1

1

'

'

3.4

5.25

'

'

'

'

'

Unit price

'

'

'

'

'

$2.85

$4.05

'

'

'

'

'

'

'

'

'

Underwriters purchased Units per price

'

'

'

'

'

'

'

'

'

$2.68

$3.81

'

'

'

'

'

Discount rate on public offering price

'

'

'

'

'

'

'

'

'

6.00%

6.00%

'

'

'

'

'

Warrants issued, expire period from date of issuance

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

'

'

'

'

Proceeds from issuance of common stock

16,612,000

19,489,000

'

'

'

15,800,000

18,400,000

'

'

'

'

'

'

'

'

'

Warrants, fair value

'

'

$3,300,000

'

$3,700,000

'

'

'

'

'

'

'

'

'

'

'

Warrants, risk free interest rate

'

'

1.00%

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

Warrants, volatility

'

'

70.00%

'

70.00%

'

'

'

'

'

'

'

'

'

'

'

Warrants, term

'

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase shares of common stock

'

'

'

'

'

'

'

'

'

3,000,000

2,469,136

'

'

'

'

'

Stockholders_Equity_Summary_of

Stockholders Equity - Summary of Warrant Activity (Detail) (USD $)	9 Months Ended	12 Months Ended	21 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013
Common shares Issuable upon Exercise	'	'	'
Beginning balance	3,205,492	'	'
Issued	3,000,000	'	'
Exercised	-20,000	'	'
Cancelled	0	'	'
Ending balance	6,185,492	3,205,492	6,185,492
Exercisable at September 30, 2013	6,185,492	'	6,185,492
Weighted Average Exercise Price	'	'	'
Beginning balance	$4.56	'	'
Issued	$3.40	'	'
Exercised	$2.27	'	'
Cancelled	$0	'	'
Ending balance	$4.01	$4.56	$4.01
Exercisable at September 30, 2013	$4.01	'	$4.01
Weighted Average Contractual Life	'	'	'
Beginning balance	'	'3 years 9 months 18 days	'
Outstanding at September 30, 2013	'	'	'3 years 9 months 18 days
Exercisable at September 30, 2013	'	'	'3 years 9 months 18 days

Equity_Compensation_Plans_Addi

Equity Compensation Plans - Additional Information (Detail) (USD $)	9 Months Ended	1 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2013	31-May-13	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
		2012 Plan	2012 Plan	2012 Plan	2012 Plan	2006 Plan
				Minimum	Maximum
Share-based Compensation Arrangement by Share-based Payment Award	'	'	'	'	'	'
Common shares authorized for issuance	6.8	'	3	'	'	3.8
Common shares authorized for issuance during period	'	1	'	'	'	'
Options vesting period	'	'	'	'1 year	'4 years	'
Term of options	'	'	'	'	'10 years	'
Common shares available for future grants	3	'	'	'	'	'
Weighted average grant date fair value	$1.55	'	'	'	'	'

Equity_Compensation_Plans_Summ

Equity Compensation Plans - Summary of Stock Option Activity (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Number of shares	'	'
Beginning balance	2,213,916	'
Granted	1,253,771	'
Exercised	0	'
Cancelled	-834,752	'
Ending balance	2,632,935	2,213,916
Vested or expected to vest at September 30, 2013	2,562,899	'
Exercisable at September 30, 2013	1,027,577	'
Weighted-Average Exercise Price	'	'
Beginning balance	$3.71	'
Granted	$2.46	'
Exercised	$0	'
Cancelled	$3.48	'
Ending balance	$3.19	$3.71
Vested or expected to vest at September 30, 2013	$3.19	'
Exercisable at September 30, 2013	$4.07	'
Weighted Average Remaining Contractual Life (in years)	'	'
Outstanding	'7 years 6 months	'8 years 10 months 24 days
Vested or expected to vest at September 30, 2013	'7 years 6 months	'
Exercisable at September 30, 2013	'4 years 10 months 24 days	'
Total Aggregate Intrinsic Value	'	'
Outstanding at December 31, 2012	$0	'
Outstanding at September 30, 2013	11,525	0
Vested or expected to vest at September 30, 2013	11,218	'
Exercisable at September 30, 2013	$3,275	'

Litigation_Additional_Informat

Litigation - Additional Information (Detail) (Scomedica)	Sep. 30, 2013	Sep. 30, 2013
In Millions, unless otherwise specified	USD ($)	EUR (€)
Loss Contingencies [Line Items]	'	'
Loss contingency liability	$5.50	€ 4.10